Cytodyn, Inc.

This study tested whether a monoclonal antibody called PRO 140 could keep HIV under control when used alone, replacing standard combination antiretroviral therapy (ART). Twenty adults with HIV who had completed a prior study without virus rebound were enrolled. The main goal was …

This study looked at whether HIV patients who already had the virus under control could keep it that way by taking only PRO 140 (a weekly shot) instead of their usual combination of HIV medicines. It included 56 adults who had completed a previous study. The trial was stopped ear…

This study gave HIV patients who had already completed an earlier trial continued access to a weekly injection of PRO 140 along with their regular HIV medications. The goal was to see if the drug could keep the virus under control and be safe over a longer period. A total of 43 p…

This study tested a combination of the drug leronlimab and chemotherapy (carboplatin) in people with a specific type of advanced triple-negative breast cancer that has a marker called CCR5. The goal was to find the best dose and see if it could slow cancer growth. Only 10 people …